Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
The European Laboratory Research & Innovation Group (ELRIG) UK today announced the keynote speakers for its upcoming Research and Innovation conference taking place at the University of Manchester from 20–21 March.
Australian researchers have discovered a new way that epithelial cells, which form layers in organs like the skin and stomach, attach to one another, and how they perceive growth signals at these attachments, helping them form tissues of the right size and shape.
A comprehensive new study from deCODE genetics, a subsidiary of Amgen, published today in Nature Genetics, provides insights into the epidemiology and somatic and germline genetics of clonal hematopoiesis.
In a recent study, a novel combination of treatments was discovered to effectively reduce the growth of pancreatic cancer in mice by inhibiting cancer cells from seeking fuel sources.
Cancer cells can boost tumor development by hijacking enhancer DNA, which is typically utilized when tissues and organs form, according to researchers at the University of Toronto (U of T).
Fresh discoveries about a type of immune cells could give lung cancer patients a more accurate prognosis and better identify who will benefit from immunotherapies.
Cancer cells can evade the body's immune defenses by exploiting a normally helpful and ubiquitous group of molecules known as mucins.
A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer?"
Novel blood testing technology being developed by researchers at the Johns Hopkins Kimmel Cancer Center that combines genome-wide sequencing of single molecules of DNA shed from tumors and machine learning may allow earlier detection of lung and other cancers.
Chemotherapy and radiotherapy aim to destroy cancer cells by inducing DNA double-strand breaks – damage that, once inflicted, usually causes the cells to die. But damage to a cell's genetic material also activates a signaling pathway called IKK/NF-κB that helps prevent cell death, thus limiting the success of these treatments in patients.
Lung cancer, one of the most aggressive forms of cancer, continues to be a leading cause of death worldwide. Although several new therapies have been developed for this disease, it has a poor prognosis in its advanced stages.
Discussions of cancer often stress the genetic mutations that drive disease by altering the normal function of cellular proteins.
Genomic studies of cancer patients have revealed thousands of mutations linked to tumor development.
Despite the astounding advances made in understanding the biologic underpinnings of cancer, many cancers are missing obvious genetic drivers.
Lung cancer patients who may not react well to immunotherapy (ICB) could be identified by the oncogenic activation of MYC, an important gene in the development of cancer.
A potential immunotherapy method for treating metastatic melanoma is adoptive cell therapy (ACT). The method, which utilizes the use of immune cells extracted from the patient’s own tumors, could offer cancer patients new options for treatment by eschewing radiation therapies and harsh chemotherapy drugs.
A research team co-led by chemists from City University of Hong Kong recently discovered novel, highly effective anticancer agents with tridimensional structures, which have high anticancer activity, low toxicity and the ability to overcome drug resistance in cancer cells.
Proteomics is the study and analysis of proteins in a biological system, including their structures, functions, associations, and alterations.
Cancer that has spread to areas like the lungs can apply the brakes to a natural pathway that should recruit killer T cells directly to where it has metastasized, scientists report.
Fibroblasts build and maintain the extracellular matrix, or physical scaffolding for cells, in the connective tissues within the body.